Racura presents MYC silencing data at AACR 2026
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASX Announcement
Racura Oncology Presents MYC Gene
Silencing Data by (E,E)-bisantrene at the
2026 American Association of Cancer
Research Annual Meeting
Mechanism of action data describing how (E,E)-bisantrene silences MYC gene expression was
presented at the prestigious American Association of Cancer Research (AACR) Annual Meeting
held in San Diego, 17-22 April 2026
Data demonstrates how (E,E)-bisantrene binds to and stabilises G-quadruplex (G4) structures in
the c-MYC gene promotor region, leading to silencing of the key cancer driver MYC
Presentation data supports Racura’s current and planned clinical trials
22 April 2026
Racura Oncology Limited (“Racura”) is pleased to announce that Dr Sumit Sahni, presented mechanism of
action data on (E-E)-bisantrene at the 2026 AACR Annual Meeting. The data discloses results from a range
of preclinical studies demonstrating (E,E)-bisantrene silences MYC gene expression by stabilising a G-
quadruplex (G4) DNA structure located in the promoter region of the c-MYC oncogene.
The poster presentation entitled “(E,E)-bisantrene silences c-MYC expression by stabilizing its promotor
region G-quadruplex” is attached to this announcement.
Racura Oncology Senior Scientist, Dr Sumit Sahni commented: “It was a privilege to be chosen to present
Racura’s mechanism of action data at the leading annual international cancer conference, AACR. I sincerely
thank my preclinical team colleagues and our valued collaborators for their outstanding work that has
uncovered the primary mechanism by which (E,E)-bisantrene exerts its anticancer activity. The strong
interest and positive reception this work received at the conference is very encouraging.”
-ENDS-
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to
silence cancer.
Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-
DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-
bisantrene has demonstrated therapeutic activity in cancer patients with a well-characterised safety
profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provides for
20 years of patent protection over (E,E)-bisantrene.
Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs
of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid
leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung
cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin,
where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of
Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively
exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access
to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.
If you have any questions on this announcement, or any past Racura Oncology announcements, please
visit our Interactive Announcements page.
Racura encourages all investors to go paperless by registering their details with the Company’s share
registry, Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Figure 3: SPR analysis of (E,E)-bisantrene binding to 1000 response units (RU) of:
(A) c-MYC G4 ssDNA (5'-/5Biosg/TGAGGGTGGGTAGGGTGGGTAA-3’), and (B) a
related mutant c-MYC dsDNA sequence (5'-
/5Biosg/TGAGAGTGAGTAGAGTGAGTAA-3' and 5'-TTACTCACTCTACTCACTCTCA-
3’) on a NeutrAvidin-coated sensor chip. (E,E)-bisantrene was injected in a
concentration series from 0–1000 nM over multiple sequential injections, each
lasting 300 s at a flow rate of 25 µL/min, followed by a 600 s dissociation phase.
Figure 2: Representative binding mode (34.9%
population) of (E,E)-bisantrene (orange sticks)
interaction with the c-MYC G4 (PDB ID: 2MGN).
5′ and 3′ ends of the DNA chain are indicated
by red and blue spheres, respectively. K+ ions
are indicated by purple spheres.
Circular dichroism spectroscopy established if (E,E)-bisantrene
stabilizes the c-MYC promotor G4 structure, and surface plasmon
resonance was used to measure the binding affinity. Nuclear
magnetic resonance spectroscopy was used to determine the binding
stoichiometry of (E,E)-bisantrene with c-MYC G4 and molecular
dynamics simulations identified a possible 3-dimensional structure
of the complex. Changes in c-MYC gene expression were assessed by
qPCR in selected cancer cell lines after treatment with (E,E)-
bisantrene. RNA-seq with pathway analysis was performed in lung
cancer cell lines treated with (E,E)-bisantrene.
(E,E)-bisantrene silences c-MYC expression by stabilizing its promotor region G-quadruplex
Sumit Sahni,1 Emily Ryan,1 Peter Cuthbertson,1 Feroz Ahmad,1 Kirsten Curnow,1 Nehad Elsalamouny,2 Qiang Zhu,2 Haibo Yu,2 Jinho Jang,3 Jonathan
Dickerhoff,3 Danzhou Yang,3 Emma-Jayne Proctor,2 Martina Sanderson-Smith,2 Daniel Tillett1 and Michael J. Kelso1
METHODS
BACKGROUND
CONCLUSION
(E,E)-bisantrene binds to and stabilizes the G4 DNA structure
contained within the c-MYC promotor region, leading to silencing of
c-MYC gene expression. These studies support the clinical evaluation
of (E,E)-bisantrene as a new c-MYC targeting G4 drug. Two Phase 1
clinical trials are currently underway exploring the activity of (E,E)-
bisantrene in combination with doxorubicin in advanced solid tumors
(ClinicalTrials.gov ID: NCT06815575) and in combination with
osimertinib in EGFRm NSCLC (ClinicalTrials.gov ID: Pending;
Australia New Zealand Clinical Trial Registration #2626000325303).
G-quadruplex (G4) DNA and RNA are important non-canonical
nucleic acid secondary structures that play key roles in many cellular
processes. They regulate the expression and translation of several
oncogenes, including the master cell growth regulator, c-MYC.
Bisantrene is a small-molecule anticancer agent that has been
shown to be safe and effective in >1500 clinical trial patients. This
study characterized the binding and stabilization of a G4 region in the
c-MYC gene promoter by the pure (E,E)-bisantrene isomer1 and
silencing of c-MYC gene expression in cancer cells.
This study was funded by Racura Oncology. Sumit Sahni (sumit.sahni@racuraoncology.com) is
employed by Racura Oncology.
Abstract Presentation #5751
RESULTS
Figure 5: c-MYC gene expression levels were
determined by qPCR after treatment of
breast (MDA-MB-231) and lung (PC-9 and
Osimertinib-resistant PC-9) cancer cells with
increasing concentrations of (E,E)-
bisantrene for 2 h.
Figure 1: 1H-NMR titration (guanine imino proton region) of c-MYC G4 DNA with
(E,E)-bisantrene. Conditions: 100 mM K+, pH 7.0, 25°C; DNA concentration, 150
μM; ratios of (E,E)-bisantrene/c-MYC G4 are shown.
Figure 6: RNA-Sequencing analysis of PC-9 and NCI-H820 lung cancer cells after
treatment with (E,E)-bisantrene. (A) Gene set enrichment analysis (GSEA) based on
the observed transcriptomic profile. (B) Similarity of the transcriptomic profile of
(E,E)-bisantrene to another G4 binding drug, CX-5461, by Ingenuity Pathway
Analysis.
Figure 4: Melting curves of c-MYC G4 DNA sequence in the presence of (E,E)-
bisantrene (A) or CX-5461 (B). Molar ellipticity for c-MYC G4 was determined at
265 nm using circular dichroism spectroscopy.
Molecular Dynamics
Binding Affinity
G4 Stabilization
Gene Expression Analysis
RNA-Sequencing & Pathway Analysis
1H-Nuclear Magnetic Resonance (1H-NMR)
1Racura Oncology Ltd, Sydney, Australia. 2University of Wollongong, Wollongong, Australia. 3Purdue Institute for Cancer Research, West Lafayette, Indiana, USA.
1H-NMR titration indicated that (E,E)-bisantrene binds to c-MYC G4
with a 2:1 (E,E)-bisantrene: c-MYC G4 stoichiometry (Figure 1).
Molecular dynamics simulations suggested that (E,E)-bisantrene
preferentially binds to the c-MYC G4 by stacking one molecule on
each of the top and bottom G-tetrads (Figure 2).
Surface Plasmon Resonance (SPR) analysis demonstrated that (E,E)-
bisantrene binds to the c-MYC G4 with high affinity (Figure 3A) and
showed ~1.5-fold selectivity over a related mutant c-MYC double
stranded DNA (dsDNA) sequence (Figure 3B).
(E,E)-bisantrene (Figure 4A) and CX-5461 (Pidnarulex, Figure 4B), an
investigational G4 stabilizing comparator, each dose-dependently
increased the c-MYC G4 melting temperature, confirming binding and
stabilization of the c-MYC G4.
Treatment of breast and lung cancer cells with (E,E)-bisantrene for 2
h dose-dependently suppressed c-MYC expression (Figure 5).
RNA-seq analysis in PC-9 and NCI-H820 non-small cell lung cancer
(NSCLC) cells showed thousands of differentially regulated genes
following treatment with (E,E)-bisantrene (data not shown). Gene set
enrichment analysis of the RNA-seq data showed that the most
strongly downregulated pathways were related to c-MYC (Figure 6A).
Ingenuity Pathway Analysis identified that transcriptomic profile of
(E,E)-bisantrene is similar to the G4-binding comparator CX-5461
(Figure 6B).
1Racura ASX Announcement: 2nd Oct 2025
10 100 1000 10000
0
25
50
75
100
125
(E,E)-bisantrene (nM)
c-MYC
Expression
(%)
EC50
: 322.5 + 42.6 nM
: 349.854 + 62.6 nM
: 518.143 + 85.1 nM
MDA-MB-231
PC-9
PC-9-OSi-R
Share your feedback
Discover